Press release

Press release

November 30, 2015

Interim Report Q3 2015

Follicum today reported publication of its Q3 2015 interim report in Swedish. Below is a short summary of activities during the period: Significant activities during third quarter 2015: -On 1 September the company announced that the two toxicity studies which had been ongoing since March were completed, showing positive results. -In September Follicum initiated a collaboration […]

November 23, 2015

99.36% of Follicum’s TO 1 warrants converted

The utilization period of the TO 1 series warrants issued in conjunction with Follicum’s initial public offering ended on 17 November, warrants were converted at a rate of 99.36%. This provides additional funding of about 6.96 MSEK before issuing costs to Follicum. For more information, please contact Jan Alenfall, CEO Tel +46 (0) 46 19 […]

October 26, 2015

Information about warrants

Tomorrow, October 27, 2015, the utilization period of the series TO 1 warrants issued in conjunction with Follicum’s initial public offering starts. The utilization period will run until November 17, 2015. Warrant holders are entitled to subscribe for one new share in Follicum for each warrant at a price of SEK 6.00 per share. For more […]

October 23, 2015

New date for publication of Interim Report Q3

Follicum’s Interim Report for the Q3 period (1 July to 30 September 2015) will be published later than previously communicated.  The original date for publication was the 25 November 2015, but the new date for publication has been changed to 30 November 2015. For more information, please contact: Jan Alenfall, CEO Tel: +46 (0)46 19 […]

October 15, 2015

Clinical Trial Application filed to BfArM

Follicum has filed a clinical trial application to start a clinical Phase I / II a study to both the the BfArM (the Federal Institute for Drugs and  Medical Devices in Germany) and to the Research Ethics Committee. Follicum’s intention is to initiate the study at year-end 2015/early 2016, provided that the application is accepted. […]

October 1, 2015

Follicum’s patent preliminary approved

Follicum has received a preliminary approval – a so called “Intention to Grant” – by the European Patent Office (EPO) regarding the company’s patent application for stimulation of hair growth. To read the full press release (in Swedish) please click here. For more information about Follicum’s research results, please contact: Jan Alenfall, CEO Tel +46 (0)46 19 21 […]

September 9, 2015

Cooperation initiated with research group in Berlin for the planned clinical study

As previously communicated, Follicum’s intention is to start a clinical phase I/IIa study around year-end 2015/early 2016. We can now announce that a cooperation with the Clinical Research Center for Hair and Skin Science (“CRC”) in Berlin, Germany, has been initiated regarding our planned clinical phase I/IIa study. Follicum’s intention is to submit an application […]

September 1, 2015

Follicum has completed toxicity studies

Follicum announced in March 2015  that they had started two larger toxicity studies to  add information to the two short time toxicity studies and  continue development. The short time studies were finalized in February 2015, and showed no adverse effects. The two larger toxicity studies have now been finished according to plan, showing very promising […]